Med Ex and Mounjaro: How Medical Exemptions Fit Into Your Treatment Path

Step 1 (Understand what a medical exemption certificate does (and doesn't) cover

A medical exemption certificate) or MedEx, entitles the holder to free NHS prescriptions for certain long-term conditions, including diabetes. If you hold one and your GP is prescribing Mounjaro through the NHS, your exemption should mean no prescription charge. That part is straightforward.

The complication arises when people assume the same exemption applies to a private prescription. It does not. NHS medical exemptions are a rebate mechanism within the NHS charging system; they have no legal bearing on what a private pharmacy charges for a privately written prescription. Tirzepatide for weight management is a private prescription in the vast majority of cases right now, because NHS access is still being phased in under strict criteria. So if cost is the issue, your MedEx is not the tool that helps here, what matters instead is whether you qualify for NHS treatment or, if not, what the all-in cost of private treatment looks like. You can compare what's included in any provider's price on our Mounjaro price and cost guide.

One other nuance: if you are considering Mounjaro medicine prescribed for type 2 diabetes rather than weight management, it is issued on an NHS prescription where exemptions apply normally. But that is a clinical decision based on your diagnosis, not something you can request on the grounds of cost alone.

Step 2, Check where you sit in the NHS tirzepatide rollout

NICE recommended tirzepatide for weight management in December 2024 (Technology Appraisal TA1026), and NHS England is phasing in access in cohorts. From June 2025, patients with a BMI of 40 or above plus four or more qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes) became eligible. A second cohort with BMI 35 to 39.9 and four or more of those conditions was activated in June 2026. Further cohorts follow from around March 2027.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance: the NICE-recommended adjustment is 2.5 kg/m² for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds. Every NHS patient must also take part in wraparound diet and activity support; meeting the criteria on paper does not guarantee immediate access, because GP practice participation and local commissioning both vary. Read more about medical eligibility for Mounjaro if you want the full picture of who qualifies under the NHS and private routes.

For anyone who does not meet the current NHS cohort criteria, or whose local practice is not yet participating, private treatment remains the realistic option. That is where the rest of this page is relevant.

Step 3, Know what the private clinical assessment involves

A question our prescribers hear most weeks is whether someone can just transfer an existing NHS treatment across to a private pharmacy if their GP is slow to re-prescribe. Transfers are possible, but they still require a full clinical review. The prescriber needs to see evidence of your current treatment, your recent weight, and your full medical picture before issuing a private prescription. There are no shortcuts, and any provider that implies otherwise is a red flag worth taking seriously.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, on the same day. Photo ID, live weight verification on video, and a check of your medical history all form part of the process, not to create friction, but because these medicines are genuinely potent and a prescriber's judgement matters. You can read about what Mounjaro treatment involves medically before you start. Our clinical team oversees every prescription issued through the pharmacy.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, it activates two appetite-related gut-hormone pathways, which is why its average weight-reduction figures in clinical trials have been notably strong. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported around 20–21% average body-weight reduction at the 15mg dose over 72 weeks. Those numbers come from a tightly controlled study (real-world results vary) but they are part of why NICE concluded the medicine represented value and recommended it. The NHS's own overview of tirzepatide is a useful starting point if you want the unvarnished clinical summary: the NHS medicines page for tirzepatide covers how it works, common side effects and what to watch for.

Step 4 (Identify the right next step for your situation

If you hold a MedEx for diabetes and your GP is prescribing Mounjaro on the NHS for that indication, your exemption works as normal, confirm this with your GP or NHS pharmacy. If you are looking for tirzepatide for weight management and you do not currently meet NHS cohort criteria, private treatment is the practical route. Check whether you meet the private licensed eligibility: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. BMI is one factor, not the whole picture.

If you are unsure whether your circumstances (including your medical history, current medicines or any MedEx-related diagnosis) affect your suitability, the clearest next step is a consultation with a prescriber who can review your full picture, and you can find out more about the Mounjaro medi service before booking. There is no cost to that conversation at nume. For a broader look at all weight-loss options available, our weight-loss treatment overview sets out the landscape honestly. And if you have already done your research and want to get moving, you can start your free consultation today, a real prescriber, not an algorithm, will read your answers the same day.